BioNTech SE
BNTX
$101.81
$3.053.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -7.31% | 887.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -7.31% | 887.91% | |||
| Cost of Revenue | 31.97% | 205.57% | |||
| Gross Profit | -13.90% | 1,480.14% | |||
| SG&A Expenses | -14.89% | -16.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -87.58% | 34.03% | |||
| Total Operating Expenses | -18.28% | 14.64% | |||
| Operating Income | 635.33% | 102.22% | |||
| Income Before Tax | 84.02% | 120.12% | |||
| Income Tax Expenses | 202.62% | -2,112.14% | |||
| Earnings from Continuing Operations | 27.01% | 125.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 27.01% | 125.05% | |||
| EBIT | 635.33% | 102.22% | |||
| EBITDA | 313.24% | 107.31% | |||
| EPS Basic | 27.70% | 124.93% | |||
| Normalized Basic EPS | 61.34% | 125.91% | |||
| EPS Diluted | 28.97% | 124.62% | |||
| Normalized Diluted EPS | 63.32% | 125.60% | |||
| Average Basic Shares Outstanding | -0.54% | 0.49% | |||
| Average Diluted Shares Outstanding | -1.75% | 1.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||